“It is a great pleasure to write this recommendation. Over the past two months in my new role as an MSL, Sabrina has demonstrated great mentorship and leadership abilities. I would like to express my sincere appreciation for her support in teaching me best practices and important insights to excel as an MSL. I am confident that Sabrina will continue to play a key role in supporting and leading the team to achieve great success.”
About
Passionate accomplished leader with 17 years of pharma/biotech experience within Oncology Medical Affairs & Business Development in Canada/US • Successful track record in building high-performing impactful teams to develop & execute insights-driven Medical Strategic Tactical Plans in pre/post-launch settings across Solid Tumors & Hematological Malignancies (including Cell Therapy) to accelerate access to innovative therapies • Proven success in FIH to Phase IV Clinical Research including Real World Evidence & Correlative study protocol development, multi-center participation, evidence generation & publications • Change Leader in organization re-design & culture transformation • Entrepreneurial mindset, resilient & consistent results-driven performer thriving in fast-paced evolving matrix environment • Myers-Briggs Type Indicator - INTJ
Activity
-
Exciting News! The whitepaper “Good Practices in Lung Cancer Multi-Disciplinary Teams (MDTs)” is now published as part of AstraZeneca’s MDT Aid…
Exciting News! The whitepaper “Good Practices in Lung Cancer Multi-Disciplinary Teams (MDTs)” is now published as part of AstraZeneca’s MDT Aid…
Liked by Sabrina Perri, PhD
-
One of our responsibilities as a leading organization in our industry is not only to lead our own business and people, but also to collaborate, lead,…
One of our responsibilities as a leading organization in our industry is not only to lead our own business and people, but also to collaborate, lead,…
Liked by Sabrina Perri, PhD
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
Activities and Societies: Co-President of the Experimental Medicine Graduate Students’ Society (EMGSS) of McGill University 2002-2004 Chair of the 2nd, 3rd and 4th Annual McGill Biomedical Graduate Conference (AMBGC) Organizing Committee 2001-2004 Main Organizer of the 1st Cell and Gene Therapy Quebec Colloquium 2001 EMGSS Student Representative at the Executive Academic Council. 2001-2002
Supervisor: Jacques Galipeau M.D. FRCPC, Segal Cancer Centre, Jewish General Hospital
US Army Breast Cancer Pre-Doctoral Traineeship Award
CIHR Doctoral Research Award -
-
-
-
Publications
-
Real World Everolimus Experience in Postmenopausal Women with HR+ HER2- Advanced Breast Cancer - Treat ER+ight Canadian Prospective Observational Study Second Subgroup Analysis.
European Society of Clinical Oncology (ESMO) Poster Presentation
-
Treat ER+ight Canadian Prospective Observational Study in Postmenopausal HR+ HER2- Advanced Breast Cancer Women - First Interim Analysis
American Society of Clinical Oncology (ASCO) Poster Presentation
-
Canadian Real-World Experience with Everolimus in Combination with Exemestane in Post-Menopausal HR+ HER2- Advanced Breast Cancer Women - First Subgroup Baseline Analysis from the Treat ER+ight Canadian Prospective Observational Study
Canadian Association of Pharmacy in Oncology (CAPhO) Poster Presentation
-
Treat ER+ight Canadian Prospective Observational Study in HR+ Advanced Breast Cancer: Second Interim Analysis
San Antonio Breast Cancer Symposium (SABCS) Accepted for Poster Presentation
Other authors -
-
Treat ER+ight: Treatment of Canadian Postmenopausal Women with ER+ HER2- Advanced Breast Cancer in the Real-World Setting with Hormone Therapy +/- Targeted Therapy
American Society of Clinical Oncology (ASCO) Trial-in-Progress Poster Presentation
-
Five-year experience of McGill University’s Adolescent and Young Adult Oncology Program: The challenge of serving a unique, underserved population.
Oncology Exchange
See publicationM. Palumbo, P. Kavan, D. Roberge, T. Muanza, S.R. Perri & G. Batist. Oncology Exchange; 8(2) May 2009
-
Plasminogen Kringle 5 Blocks Tumor Progression by Anti-Angiogenic and Pro-Inflammatory Pathways.
Molecular Cancer Therapeutics
S. R. Perri et al. Molecular Cancer Therapeutics 2007; 6(2) 441-449. Figure selected as Cover Art.
Other authors -
Languages
-
English
-
-
French
-
-
Italian
-
Recommendations received
2 people have recommended Sabrina
Join now to viewMore activity by Sabrina
-
Life lessons from Roger Federer’s Dartmouth Commencement speech. 1 Effortless is a myth 2 Belief in yourself has to be earned 3 Grit > Gift 4…
Life lessons from Roger Federer’s Dartmouth Commencement speech. 1 Effortless is a myth 2 Belief in yourself has to be earned 3 Grit > Gift 4…
Liked by Sabrina Perri, PhD
-
We pioneered patient identification using machine learning approach 2 years ago as part of our digital strategy. I’m thrilled to see this project…
We pioneered patient identification using machine learning approach 2 years ago as part of our digital strategy. I’m thrilled to see this project…
Liked by Sabrina Perri, PhD
-
Investing in the next generation of oncologists is crucial for the future of cancer research. At #ASCO2024, let's continue to support and mentor…
Investing in the next generation of oncologists is crucial for the future of cancer research. At #ASCO2024, let's continue to support and mentor…
Liked by Sabrina Perri, PhD
-
Ahead of today’s Investor Day, AstraZeneca has just announced a bold ambition to deliver $80bn in Total Revenue by 2030, up from around $45bn in…
Ahead of today’s Investor Day, AstraZeneca has just announced a bold ambition to deliver $80bn in Total Revenue by 2030, up from around $45bn in…
Liked by Sabrina Perri, PhD
-
Today, we revealed our bold ambition to deliver $80bn in annual revenue by 2030, up from $45bn in 2023. This will be achieved through significant…
Today, we revealed our bold ambition to deliver $80bn in annual revenue by 2030, up from $45bn in 2023. This will be achieved through significant…
Liked by Sabrina Perri, PhD
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More